Embattled Cel-Sci to tackle COVID-19 with immunotherapy platform tech LEAPS

Cel-Sci has formed a research partnership with the University of Georgia’s Center for Vaccines and Immunology to develop a drug candidate for patients at high risk of dying from COVID-19. The collaborators plan to use Cel-Sci's immunotherapy platform to design peptide-based treatments targeting the virus' nucleoprotein, which is critical to its ability to replicate.

Embattled Cel-Sci to tackle COVID-19 with immunotherapy platform tech LEAPS
Cel-Sci has formed a research partnership with the University of Georgia’s Center for Vaccines and Immunology to develop a drug candidate for patients at high risk of dying from COVID-19. The collaborators plan to use Cel-Sci's immunotherapy platform to design peptide-based treatments targeting the virus' nucleoprotein, which is critical to its ability to replicate.